Amgen vs Eli Lilly

Amgen and Eli Lilly are both well-known pharmaceutical companies that have been in the market for several decades. Both companies have a strong track record of developing innovative drugs and treatments in various therapeutic areas. Investors often compare the performance of Amgen and Eli Lilly stocks to determine which company may be a better investment option. By analyzing key financial indicators, market trends, and upcoming developments, investors can make informed decisions about investing in either Amgen or Eli Lilly stocks.

Amgen

Eli Lilly

Stock Price
Day Low	$324.03
Day High	$327.33

Year Low	$249.70
Year High	$346.85
Yearly Change	38.91%

Revenue
Revenue Per Share	$57.41
5 Year Revenue Growth	0.47%
10 Year Revenue Growth	1.12%

Profit
Gross Profit Margin	0.63%
Operating Profit Margin	0.20%
Net Profit Margin	0.10%

Stock Price
Day Low	$907.80
Day High	$926.22

Year Low	$547.61
Year High	$972.53
Yearly Change	77.60%

Revenue
Revenue Per Share	$43.20
5 Year Revenue Growth	0.81%
10 Year Revenue Growth	0.77%

Profit
Gross Profit Margin	0.81%
Operating Profit Margin	0.27%
Net Profit Margin	0.19%

Amgen

Eli Lilly

Financial Ratios
P/E ratio	55.77
PEG ratio	28.38
P/B ratio	29.46
ROE	50.41%

Payout ratio	150.06%
Current ratio	1.26
Quick ratio	0.89
Cash ratio	0.43

Dividend
Dividend Yield	2.73%
5 Year Dividend Yield	10.04%
10 Year Dividend Yield	16.31%
Amgen Dividend History

Financial Ratios
P/E ratio	112.07
PEG ratio	-32.87
P/B ratio	60.67
ROE	60.72%

Payout ratio	59.60%
Current ratio	1.11
Quick ratio	0.87
Cash ratio	0.12

Dividend
Dividend Yield	0.55%
5 Year Dividend Yield	14.97%
10 Year Dividend Yield	8.71%
Eli Lilly Dividend History

Amgen or Eli Lilly?

When comparing Amgen and Eli Lilly, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Amgen and Eli Lilly.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Amgen has a dividend yield of 2.73%, while Eli Lilly has a dividend yield of 0.55%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Amgen reports a 5-year dividend growth of 10.04% year and a payout ratio of 150.06%. On the other hand, Eli Lilly reports a 5-year dividend growth of 14.97% year and a payout ratio of 59.60%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Amgen P/E ratio at 55.77 and Eli Lilly's P/E ratio at 112.07. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Amgen P/B ratio is 29.46 while Eli Lilly's P/B ratio is 60.67.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Amgen has seen a 5-year revenue growth of 0.47%, while Eli Lilly's is 0.81%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Amgen's ROE at 50.41% and Eli Lilly's ROE at 60.72%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $324.03 for Amgen and $907.80 for Eli Lilly. Over the past year, Amgen's prices ranged from $249.70 to $346.85, with a yearly change of 38.91%. Eli Lilly's prices fluctuated between $547.61 and $972.53, with a yearly change of 77.60%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.